Seelos Therapeutics, Inc.
SEELQ Healthcare Biotechnology
Seelos Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.2 million. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow SEELQ
Seelos Therapeutics, Inc. (SEELQ) EV/Sales
As of 15 October 2026, Seelos Therapeutics, Inc. (SEELQ) trades at a EV/Sales of 0.5×. Over the past ten years it has ranged from −0.1× (March 2020) to 22,904,009× (July 2015); the current reading is higher than 15% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 2.3× | (37.06%) |
| FY2019 | 3.7× | (100.00%) |
| FY2015 | 1,172,137× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2024 | 1.3× | (70.09%) |
| Mar 2024 | 4.2× | 84.52% |
| Dec 2023 | 2.3× | (82.18%) |
| Sep 2023 | 12.9× | (65.41%) |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LYRA Lyra Therapeutics, Inc. compare | −39.2× |
| MNTRQ 9 Meters Biopharma, Inc. compare | −0.5× |
| CRIS Curis, Inc. compare | −0.4× |
| BBLG Bone Biologics Corp. compare | n/m |
| ZVSA ZyVersa Therapeutics, Inc. compare | n/m |
| SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR compare | n/m |
| ATXI Avenue Therapeutics, Inc. compare | n/m |
| BTTX Better Therapeutics, Inc. compare | n/m |
| SEELQ Seelos Therapeutics, Inc. | 0.5× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)